$COLL - On our trading list. This one sounds interesting, lots of potential but also like most biotechs will have above average risk.Collegium should continue growing in 2020 and beyond, says Cantor Fitzgerald Cantor Fitzgerald analyst Brandon Folkes reiterates an Overweight rating on Collegium Pharmaceutical with a $24 price target. The analyst remains positive on the long-term growth potential of Xtampza, which he expects to be the leading branded extended-release oxycodone over time. Collegium will build itself into one of the leading pain-focused companies, Folkes tells investors in a research note. The company has made good progress with its exclusive contracting approach on Xtampza to-date, and the wins for 2020 "could be the significant catalyst needed to make it the leading branded long-acting oxycodone in the market," contends the analyst. $COLL, Collegium Pharmaceutical, Inc. / H1 Disclosure: I may trade in the ticker symbols mentioned, both long or short. My articles represent my personal opinion and analysis and should not be taken as investment advice. Readers should do their own research before making decisions to buy or sell securities. Trading and investing include risks, including loss of principal. If you liked this article, please click the LIKE (thumbs up) button. Feel free to leave any comments, question, or opinions. (Sign-up if you haven't already done so). Follow us/bookmark us and check back occasionally for additional articles or comments on our page... Wild Tiger Trading - start/main page